USTMA
Patient access to ADAMTS13 testing

FAST4TMA

Testing access made easier. FAST4TMA is a USTMA patient access program for eligible patients in the United States with suspected thrombotic microangiopathy (TMA) who need access to ADAMTS13 testing. The program may also support ongoing monitoring when clinically appropriate.

Request FAST4TMA Access

The focus is access. FAST4TMA helps address barriers by coordinating an appropriate testing pathway, specimen-collection options, and laboratory logistics. It does not replace emergency evaluation, local testing protocols, or treatment decisions.
Who the program serves

Testing access for patients with suspected TMA

Outpatients

Coordinate a practical testing pathway.

  • Support for eligible patients with suspected TMA who need ADAMTS13 testing.
  • Help navigating current request and ordering requirements.
  • Specimen-collection options may include mobile phlebotomy when available.
  • Monitoring support may be available when clinically appropriate.
Inpatients

Connect the care team to an available pathway.

  • Support for eligible hospitalized patients undergoing evaluation for suspected TMA.
  • Help identifying an appropriate ADAMTS13 laboratory and collection route.
  • Coordination of access and logistics with the treating team.
  • Necessary emergency care and treatment should not wait for FAST4TMA coordination.
How it works

From an access need to a testing plan

1

Request access support

Identify the patient’s care setting and the suspected TMA evaluation or clinically appropriate monitoring need.

2

Confirm the pathway

USTMA reviews eligibility and coordinates the available collection and laboratory options.

3

Complete testing and follow-up

The treating team uses the confirmed pathway and receives results according to the laboratory’s current process.

Program eligibility, collection options, laboratories, and operational workflows can change. Confirm current instructions with USTMA for each request.